Streetbeat News

CYBN

Cybin Inc.

https://www.cybin.com

Industry

Biotechnology

Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.

Open

11.82

Mkt cap

232M

Volume

2.1M

High

12.95

P/E Ratio

-2.14

52-wk high

21.66

Low

11.30

Div yield

N/A

52-wk low

6.50

Cybin Inc. has initiated a Phase 3 program named PARADIGM to evaluate CYB003 for treating Major Depressive Disorder. The company also reported its second-quarter financial results.

Portfolio Pulse from

November 13, 2024 | 12:45 pm

Cybin Inc. has secured a US patent for its CYB005 phenethylamines program, focusing on non-hallucinogenic treatments for CNS disorders. This patent supports Cybin's innovative development beyond its clinical tryptamine programs. The company is also advancing its CYB003 and CYB004 programs, with significant upcoming trials and results expected in 2024.

Portfolio Pulse from Vandana Singh

October 24, 2024 | 11:01 am

Cybin is evaluating non-hallucinogenic dosing of its preclinical candidate CYB005 for treating CNS disorders.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 11:00 am

Cybin has announced the grant of its first U.S. Composition of Matter Patent for its CYB005 phenethylamines program, marking a significant milestone for the company.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 11:00 am

The DEA is proposing significant increases in production quotas for marijuana compounds and psychedelics like psilocybin and ibogaine to support research and clinical trials. This move reflects growing interest in these substances for medical and scientific purposes.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 5:41 pm

Canaccord Genuity has maintained its Buy rating on Cybin (AMEX:CYBN) but lowered the price target from $114 to $96.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 3:12 pm

Cybin Inc. is set to initiate a pivotal Phase 3 study for CYB003 in Major Depressive Disorder imminently, with 12-month efficacy data from its Phase 2 study expected in early Q4 2024. Additionally, Phase 2 results for CYB004 in Generalized Anxiety Disorder are anticipated by the end of 2024 or early 2025. The company has strengthened its R&D team with new leadership.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 9:40 pm

The cannabis and psychedelics industries are experiencing significant leadership changes. Maryland's Cannabis Chief, Will Tilburg, is resigning after overseeing a successful transition to adult-use cannabis with $1.1 billion in sales. In Massachusetts, a legal battle involving the Cannabis Control Commission continues. Companies like 1933 Industries, Cybin Inc., and Ascend Wellness Holdings are undergoing board and executive changes.

Portfolio Pulse from Jelena Martinovic

September 06, 2024 | 6:23 pm

HC Wainwright & Co. analyst Patrick Trucchio has reiterated a Buy rating for Cybin (AMEX:CYBN) and maintained a price target of $5.

Portfolio Pulse from Benzinga Newsdesk

August 23, 2024 | 11:31 am

Cybin has completed an FDA Type B initial breakthrough therapy meeting and plans to initiate a Phase 3 program for CYB003 in treating major depressive disorder by late summer.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:40 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.